Literature DB >> 26163301

Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review.

Konstantinos H Katsanos1, Giulia Roda1, Alexandre Brygo2, Emmanuel Delaporte3, Jean-Frédéric Colombel4.   

Abstract

Oral cancer is historically linked to well-known behavioural risk factors such as tobacco smoking and alcohol consumption. Other risk factors include age over 40, male sex, several dietary factors, nutritional deficiencies, viruses, sexually transmitted infections, human papillomavirus, chronic irritation, and possibly genetic predisposition. Precancerous lesions in the oral cavity include leukoplakia, erythroplakia, and lichen planus. Histology of oral cancer varies widely but the great majority are squamous cell carcinomas.Epidemiological studies and cancer registries have shown a consistently increased risk of oral malignancies in kidney, bone marrow, heart, or liver transplantation, in graft vs host disease, and in patients with HIV infection. Because of the increasing use of immunosuppressive drugs in patients with inflammatory bowel disease, it is useful to more accurately delineate the consequences of chronic immunosuppression to the oral cavity. Oral cancer and precancerous oral lesions in patients with inflammatory bowel disease [IBD] have been scarcely reported and reviews on the topic are lacking.We conducted a literature search using the terms and variants of all cancerous and precancerous oral manifestations of inflammatory bowel diseases. By retrieving the existing literature, it is evident that patients with IBD belong to the high-risk group of developing these lesions, a phenomenon amplified by the increasing HPV prevalence. Education on modifiable risk behaviours in patients with oral cancer is the cornerstone of prevention.Oral screening should be performed for all IBD patients, especially those who are about to start an immunosuppressant or biological drug.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; anti-TNF-α; azathioprine; biological therapies; immunosuppressant; oral cancer; oral malignancy; oral precancerous lesions; ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 26163301     DOI: 10.1093/ecco-jcc/jjv122

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  11 in total

1.  Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic.

Authors:  Sheena Crosby; Michael J Schuh; Freddy Caldera; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-01

2.  Oral Cancer in a Patient Receiving Mercaptopurine for Ulcerative Colitis.

Authors:  Bhavik Desai; John Svirsky
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

3.  Noninvasive assessment of oral lesions using elastic light single-scattering spectroscopy: a pilot study.

Authors:  Aslinur Sircan-Kucuksayan; Neslihan Yaprak; Alper Tunga Derin; İrem Hicran Ozbudak; Murat Turhan; Murat Canpolat
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-03       Impact factor: 2.503

4.  Inferring novel genes related to oral cancer with a network embedding method and one-class learning algorithms.

Authors:  Lei Chen; Yu-Hang Zhang; Guohua Huang; Xiaoyong Pan; Tao Huang; Yu-Dong Cai
Journal:  Gene Ther       Date:  2019-08-27       Impact factor: 5.250

Review 5.  Crohn's Disease and the Risk of Cancer.

Authors:  Evie Carchman
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

6.  Binding sites of miRNA on the overexpressed genes of oral cancer using 7mer-seed match.

Authors:  Manal A A Moustafa; Durbba Nath; John J Georrge; Supriyo Chakraborty
Journal:  Mol Cell Biochem       Date:  2022-02-18       Impact factor: 3.396

Review 7.  Practical Approaches to "Top-Down" Therapies for Crohn's Disease.

Authors:  Aranzazu Jauregui Amezaga; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2016-07

8.  Oral manifestations in inflammatory bowel disease: A cross-sectional study in Isfahan.

Authors:  Faezeh Khozeimeh; Hadi Shakerin; Hamed Daghaghzadeh; Fereshteh Najarzadegan; Zahra Golestannejad; Peyman Adibi
Journal:  Dent Res J (Isfahan)       Date:  2021-02-23

Review 9.  Long non‑coding RNAs are novel players in oral inflammatory disorders, potentially premalignant oral epithelial lesions and oral squamous cell carcinoma (Review).

Authors:  Kaiying Zhang; Wei Qiu; Buling Wu; Fuchun Fang
Journal:  Int J Mol Med       Date:  2020-06-03       Impact factor: 4.101

Review 10.  Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer.

Authors:  Aranzazu Jauregui-Amezaga; Séverine Vermeire; Hans Prenen
Journal:  Ann Gastroenterol       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.